Use of ondansetron in palliative medicine

Journal of Pain and Symptom Management
D C CurrowN J Cooney

Abstract

Ondansetron was the first of several selective 5-hydroxytryptamine (5-HT3) antagonists to be available as an antiemetic. Its uses in the setting of highly and moderately emetogenic chemotherapy and radiotherapy are well established. Ondansetron has also been used to manage nausea and vomiting in other patients. We report a retrospective analysis of its use in all 16 patients who were commenced on ondansetron after admission to our institution for nausea and/or vomiting over a 4-year period. Nine patients had advanced human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), and seven had malignancy. These patients were not undergoing disease-modifying treatment and had inadequate responses to therapeutic doses of standard antiemetics, used either singly or in combination. Responses were independently reviewed and graded by two investigators. Response was judged at 48 hr after commencing therapy. Potential causes of nausea were also reviewed. Overall, 13 of 16 [81%, 95% confidence interval (CI) 54%-96%] derived benefit. Twelve of 15 patients (80%) with nausea had a demonstrable improvement, and ten of 14 patients (71%) with vomiting also improved. Eight of ten patients (80%) admitted with nausea and/or vomiting...Continue Reading

Citations

Jun 19, 2001·Primary Care·J L Abrahm, L Snyder
May 15, 1998·Seminars in Oncology Nursing·J L Abrahm
Nov 6, 1998·Journal of Pain and Symptom Management·S MercadanteR Serretta
Oct 2, 1998·Journal of Clinical Pharmacy and Therapeutics·G M PetersonP F Dunne
Jul 12, 2003·Journal of Palliative Medicine·W Clay Jackson, Laura Tavernier
Dec 24, 2004·The American Journal of Nursing·Anne Haughney
Sep 2, 2011·The Oncologist·William IrvinDeborah K Mayer
Oct 4, 2011·Clinical Interventions in Aging·Paul GlareRoma Tickoo
Dec 20, 2008·Drugs·Paul A GlareJanet R Hardy
May 7, 2014·Journal of Pain and Symptom Management·Guillemette LavalUNKNOWN French Society for Digestive Cancer
Mar 22, 2000·Mayo Clinic Proceedings·C L LoprinziE A Perez
Oct 14, 2008·International Journal of Pharmaceutics·Yara Popst ArmandoCristina Helena dos Reis Serra
Oct 16, 2007·Pediatric Clinics of North America·Gina Santucci, Jennifer W Mack
Aug 13, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·H U De SchepperM Camilleri
Apr 28, 2000·Clinics in Geriatric Medicine·J L Abrahm
Jul 13, 2005·Pediatric Clinics of North America·Tammy KangChris Feudtner
Nov 15, 2002·Pediatric Clinics of North America·Joanne WolfeJoanne Hilden
Jun 4, 2019·European Journal of Hospital Pharmacy. Science and Practice·María Espinosa-BoschCatalina Bosch-Ojeda
Sep 21, 2018·Frontiers in Pharmacology·Gareth J Sanger, Paul L R Andrews

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.